Clearside Biomedical Inc CLSD shares are trading higher Friday after the company reported better-than-expected fourth-quarter financial results.
Clearside reported quarterly revenue of $25.69 million, which beat the $17.77 million estimate. Clearside said it earned 31 cents per share, which beat the estimate of 16 cents per share. In the same quarter last year, Clearside reported an earnings loss of 14 cents per share.
Clearside Biomedical is a U.S.-based clinical biopharmaceutical company, engaged in developing pharmacological therapies to treat blinding disease of the eye.
See Also: Guardforce Shares Jump 120%: Why The Security Stock Is Soaring Today
CLSD 52-Week Range: $1.31 - $7.73
Clearside shares were up 31.1% at $1.77 at time of publication.
Photo: Belova59 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.